Beyond hemoglobin polymerization: Mitochondrial pathobiology and therapeutic frontiers in sickle cell disease

Area of Science:

• Hematology
• Molecular Biology
• Pathophysiology

Background:

• Sickle cell disease (SCD) is a genetic blood disorder caused by HBB gene mutation, leading to sickle-shaped red blood cells.
• Traditional SCD research focused on vaso-occlusion and hemolysis, but emerging evidence highlights mitochondrial dysfunction's role.
• Mitochondria are increasingly recognized as central regulators in complex diseases like SCD.

Purpose of the Study:

• To review the role of mitochondrial dysfunction in SCD clinical features and outcomes.
• To integrate mitochondrial dynamics, inter-organelle communication, and immune activation in SCD pathophysiology.
• To explore therapeutic potential of targeting mitochondrial pathways in SCD management.

Main Methods:

• Literature review synthesizing current research on mitochondrial dysfunction in SCD.
• Integration of findings on mitochondrial dynamics, organelle crosstalk, and immune responses.
• Analysis of mitochondria's role in erythropoiesis, endothelial function, organ damage, and vaso-occlusion.

Main Results:

• Mitochondria are implicated in inflammation control, disease progression, and immune responses in SCD.
• Mitochondrial dysfunction impacts erythropoiesis, endothelial dysfunction, organ damage, and vaso-occlusion.
• Mitochondrial dynamics and inter-organelle communication are critical in SCD pathogenesis.

Conclusions:

• Mitochondrial dysfunction is a key driver of SCD pathophysiology and clinical manifestations.
• Targeting mitochondrial pathways presents a novel and promising therapeutic avenue for SCD.
• Further research into mitochondrial mechanisms can unlock new dimensions in SCD management.